Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
3 May 24
8-K
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
3 May 24
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
S-8
Registration of securities for employees
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
8-K
Other Events
9 Feb 24
424B5
Prospectus supplement for primary offering
9 Feb 24
8-K
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
8 Jan 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
8-K
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Regulation FD Disclosure
3 Nov 23
8-K
Regulation FD Disclosure
18 Sep 23
8-K
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
10 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Amendments to Articles of Incorporation or Bylaws
27 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
S-8
Registration of securities for employees
23 Mar 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
23 Mar 23
8-K
Entry into a Material Definitive Agreement
22 Mar 23
8-K
Other Events
10 Jan 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 22
8-K
Changes in Registrant's Certifying Accountant
7 Sep 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
11 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 22
EFFECT
Notice of effectiveness
23 May 22
CORRESP
Correspondence with SEC
18 May 22
UPLOAD
Letter from SEC
13 May 22
S-3
Shelf registration
10 May 22
10-Q
2022 Q1
Quarterly report
10 May 22
Latest ownership filings
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
PFM Health Sciences, LP
14 Feb 24
SC 13G
BANK OF AMERICA CORP /DE/
13 Feb 24
SC 13G/A
Rubric Capital Management LP
12 Feb 24
4
Michael B. Atkins
4 Jan 24
3
Michael B. Atkins
4 Jan 24
4
Timothy W. Trost
4 Jan 24
4
Ellen Lubman
4 Jan 24
4
Randi Isaacs
4 Jan 24
4
Chulani Karunatilake
4 Jan 24
4
Cynthia Seidel-Dugan
4 Jan 24
4
DANIEL J HICKLIN
4 Jan 24
SC 13G
ADAGE CAPITAL PARTNERS GP, L.L.C.
21 Dec 23
4
Peter Kolchinsky
23 Jun 23
4
Briggs Morrison
23 Jun 23
4
LUKE EVNIN
23 Jun 23
4
Alon Lazarus
23 Jun 23
4
Derek DiRocco
23 Jun 23
4
Meeta Chatterjee
23 Jun 23
4
Michael A. Sherman
23 Jun 23
SC 13G
Rubric Capital Management LP
10 Feb 23
SC 13G
PFM Health Sciences, LP
17 Jan 23
SC 13G/A
PFM Health Sciences, LP
17 Jan 23
4
Peter Kolchinsky
10 Jan 23
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
10 Jan 23
4
DANIEL J HICKLIN
9 Jan 23
4
Ellen Lubman
9 Jan 23
4
Cynthia Seidel-Dugan
9 Jan 23
4
Chulani Karunatilake
9 Jan 23
4
Timothy W. Trost
9 Jan 23
4
Reid Leonard
9 Jan 23
4
Randi Isaacs
9 Jan 23
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
12 Aug 22
4
Peter Kolchinsky
3 Jun 22
4
LUKE EVNIN
3 Jun 22
4
Derek DiRocco
3 Jun 22
4
Briggs Morrison
3 Jun 22
4
Chulani Karunatilake
3 Jun 22
4
Michael A. Sherman
3 Jun 22
4
Alon Lazarus
3 Jun 22